{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T16:11:05Z","timestamp":1782403865737,"version":"3.54.5"},"reference-count":25,"publisher":"BMJ","issue":"2","license":[{"start":{"date-parts":[[2020,8,14]],"date-time":"2020-08-14T00:00:00Z","timestamp":1597363200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["RMD Open"],"accepted":{"date-parts":[[2020,8,10]]},"published-print":{"date-parts":[[2020,9]]},"abstract":"<jats:sec id=\"s1\">\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>Patients with inflammatory rheumatic diseases (IRD) infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) may be at risk to develop a severe course of COVID-19. The influence of immunomodulating drugs on the course of COVID-19 is unknown. To gather knowledge about SARS-CoV-2 infections in patients with IRD, we established a registry shortly after the beginning of the pandemic in Germany.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec id=\"s2\">\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Using an online questionnaire (<jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/www.COVID19-rheuma.de\/\">www.COVID19-rheuma.de<\/jats:ext-link>), a nationwide database was launched on 30 March 2020, with appropriate ethical and data protection approval to collect data of patients with IRD infected with SARS-CoV-2. In this registry, key clinical and epidemiological parameters\u2014for example, diagnosis of IRD, antirheumatic therapies, comorbidities and course of the infection\u2014are documented.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec id=\"s3\">\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Until 25 April 2020, data from 104 patients with IRD infected with SARS-CoV-2 were reported (40 males; 63 females; 1 diverse). Most of them (45%) were diagnosed with rheumatoid arthritis, 59% had one or more comorbidities and 42% were treated with biological disease-modifying antirheumatic drugs. Hospitalisation was reported in 32% of the patients. Two-thirds of the patients already recovered. Unfortunately, 6 patients had a fatal course.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec id=\"s4\">\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>In a short time, a national registry for SARS-CoV2-infected patients with IRD was established. Within 4 weeks, 104 cases were documented. The registry enables to generate data rapidly in this emerging situation and to gain a better understanding of the course of SARS-CoV2-infection in patients with IRD, with a distinct focus on their immunomodulatory therapies. This knowledge is valuable for timely information of physicians and patients with IRD, and shall also serve for the development of guidance for the management of patients with IRD during this pandemic.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/rmdopen-2020-001332","type":"journal-article","created":{"date-parts":[[2020,9,2]],"date-time":"2020-09-02T10:05:40Z","timestamp":1599041140000},"page":"e001332","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":42,"title":["National registry for patients with inflammatory rheumatic diseases (IRD) infected with SARS-CoV-2 in Germany (ReCoVery): a valuable mean to gain rapid and reliable knowledge of the clinical course of SARS-CoV-2 infections in patients with IRD"],"prefix":"10.1136","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2982-8253","authenticated-orcid":false,"given":"Rebecca","family":"Hasseli","sequence":"first","affiliation":[{"name":"Department of Rheumatology and Clinical Immunology, Campus Kerckhoff, Justus-Liebig-University Giessen, Giessen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulf","family":"Mueller-Ladner","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Clinical Immunology, Campus Kerckhoff, Justus-Liebig-University Giessen, Giessen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tim","family":"Schmeiser","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Immunology, Saint Josef Hospital, Wuppertal, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bimba F","family":"Hoyer","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Clinical Immunology, Clinic for Internal Medicine I, University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Krause","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Clinical Immunology and Osteology, Immanuel Hospital Berlin, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanns-Martin","family":"Lorenz","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, University of Heidelberg, Heidelberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2456-4049","authenticated-orcid":false,"given":"Anne Constanze","family":"Regierer","sequence":"additional","affiliation":[{"name":"Epidemiology Unit, German Rheumatism Research Centre, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jutta G","family":"Richter","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Hiller Research Unit, Heinrich-Heine-University, Medical Faculty, Duesseldorf, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anja","family":"Strangfeld","sequence":"additional","affiliation":[{"name":"Epidemiology Unit, German Rheumatism Research Centre, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reinhard E","family":"Voll","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Clinical Immunology, University Medical Center, Faculty of Medicine, Albert-Ludwigs University of Freiburg, Freiburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Pfeil","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine III, University Hospital Jena, Jena, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hendrik","family":"Schulze-Koops","sequence":"additional","affiliation":[{"name":"Division of Rheumatology and Clinical Immunology, Department of Internal Medicine IV, University of Munich, Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christof","family":"Specker","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Clinical Immunology, KEM Kliniken Essen-Mitte,Essen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2020,9,2]]},"reference":[{"key":"2025090312273197000_6.2.e001332.1","doi-asserted-by":"crossref","unstructured":"Dai H , Zhang X , Xia J , et al. High-resolution chest CT features and clinical characteristics of patients infected with COVID-19 in Jiangsu, China. Int J Infect Dis 2020. doi: 10.1016\/j.ijid.2020.04.003","DOI":"10.1016\/j.ijid.2020.04.003"},{"key":"2025090312273197000_6.2.e001332.2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.2648"},{"key":"2025090312273197000_6.2.e001332.3","unstructured":"John Hopkins University Medicine . Coronavirus resource center. Available https:\/\/coronavirus.jhu.edu\/map.html"},{"key":"2025090312273197000_6.2.e001332.4","doi-asserted-by":"crossref","unstructured":"Schulze-Koops H , Specker C , Iking-Konert C , et al. Preliminary recommendations of the German Society of Rheumatology (DGRh eV) for the management of patients with inflammatory rheumatic diseases during the SARS-CoV-2\/COVID-19 pandemic. Ann Rheum Dis 2020. doi: 10.1136\/annrheumdis-2020-217628","DOI":"10.1136\/annrheumdis-2020-217628"},{"key":"2025090312273197000_6.2.e001332.5","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1002\/art.41301","article-title":"American College of Rheumatology guidance for the management of adult patients with rheumatic disease during the COVID-19 pandemic","volume":"72","author":"Mikuls","year":"2020","journal-title":"Arthritis Rheumatol (Hoboken, NJ)"},{"key":"2025090312273197000_6.2.e001332.6","doi-asserted-by":"crossref","unstructured":"Schmeiser T , Broll M , Dormann A , et al. A cross sectional study on patients with inflammatory rheumatic diseases in terms of their compliance to their immunosuppressive medication during COVID-19 pandemic. Z Rheumatol 2020. doi: 10.1007\/s00393-020-00800-8","DOI":"10.1007\/s00393-020-00800-8"},{"key":"2025090312273197000_6.2.e001332.7","unstructured":"Robert-Koch-Institute . Daily situation report of the robert koch institute - 25-Apr-2020. Available https:\/\/www.rki.de\/DE\/Content\/InfAZ\/N\/Neuartiges_Coronavirus\/Situationsberichte\/2020-04-25-de.pdf?__blob=publicationFile"},{"key":"2025090312273197000_6.2.e001332.8","doi-asserted-by":"publisher","DOI":"10.1002\/art.10524"},{"key":"2025090312273197000_6.2.e001332.9","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1093\/rheumatology\/key165","article-title":"Management of inflammatory rheumatic conditions in the elderly","volume":"58","author":"Lahaye","year":"2019","journal-title":"Rheumatology (Oxford)"},{"key":"2025090312273197000_6.2.e001332.10","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1186\/s13075-019-1997-5","article-title":"Comparing the burdens of opportunistic infections among patients with systemic rheumatic diseases: a nationally representative cohort study","volume":"21","author":"Hsu","year":"2019","journal-title":"Arthritis Res Ther"},{"key":"2025090312273197000_6.2.e001332.11","doi-asserted-by":"crossref","first-page":"299","DOI":"10.4081\/reumatismo.2012.299","article-title":"Incidence of influenza-like illness into a cohort of patients affected by chronic inflammatory rheumatism and treated with biological agents","volume":"64","author":"Bello","year":"2012","journal-title":"Reumatismo"},{"key":"2025090312273197000_6.2.e001332.12","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1002\/acr2.11064","article-title":"Risk of serious infection in patients with rheumatoid arthritis treated with biologic versus nonbiologic disease-modifying antirheumatic drugs","volume":"1","author":"Ozen","year":"2019","journal-title":"ACR Open Rheumatol"},{"key":"2025090312273197000_6.2.e001332.13","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1002\/acr.21928","article-title":"Incidence and time trends of herpes zoster in rheumatoid arthritis: a population-based cohort study","volume":"65","author":"Veetil","year":"2013","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2025090312273197000_6.2.e001332.14","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2015-207838"},{"key":"2025090312273197000_6.2.e001332.15","doi-asserted-by":"crossref","unstructured":"Choudhary R , Sharma AK . Potential use of hydroxychloroquine, ivermectin and azithromycin drugs in fighting COVID-19: trends, scope and relevance. New Microbes New Infect 2020;100684. doi: 10.1016\/j.nmni.2020.100684","DOI":"10.1016\/j.nmni.2020.100684"},{"key":"2025090312273197000_6.2.e001332.16","doi-asserted-by":"crossref","unstructured":"Sinha N , Balayla G . Hydroxychloroquine and COVID-19. Postgrad Med J 2020. doi: 10.1136\/postgradmedj-2020-137785","DOI":"10.1136\/postgradmedj-2020-137785"},{"key":"2025090312273197000_6.2.e001332.17","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2020.105954"},{"key":"2025090312273197000_6.2.e001332.18","doi-asserted-by":"crossref","first-page":"105982","DOI":"10.1016\/j.ijantimicag.2020.105982","article-title":"Cytokine storm and immunomodulatory therapy in COVID-19: role of chloroquine and anti-IL-6 monoclonal antibodies","volume":"55","author":"Zhao","year":"2020","journal-title":"Int J Antimicrob Agents"},{"key":"2025090312273197000_6.2.e001332.19","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.m1198","article-title":"COVID-19: risk factors for severe disease and death","volume":"368","author":"Jordan","year":"2020","journal-title":"BMJ."},{"key":"2025090312273197000_6.2.e001332.20","doi-asserted-by":"crossref","unstructured":"Schulze-Koops H , Krueger K , Vallbracht I , et al. Increased risk for severe COVID-19 in patients with inflammatory rheumatic diseases treated with rituximab. Ann Rheum Dis 2020. doi: 10.1136\/annrheumdis-2020-218075","DOI":"10.1136\/annrheumdis-2020-218075"},{"key":"2025090312273197000_6.2.e001332.21","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-217871"},{"key":"2025090312273197000_6.2.e001332.22","doi-asserted-by":"publisher","DOI":"10.2353\/ajpath.2008.071008"},{"key":"2025090312273197000_6.2.e001332.23","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.1585"},{"key":"2025090312273197000_6.2.e001332.24","doi-asserted-by":"publisher","DOI":"10.1006\/mpat.1995.0056"},{"key":"2025090312273197000_6.2.e001332.25","doi-asserted-by":"publisher","DOI":"10.1002\/1521-4141(200109)31:9<2566::AID-IMMU2566>3.0.CO;2-L"}],"container-title":["RMD Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/rmdopen-2020-001332","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T19:27:40Z","timestamp":1756927660000},"score":1,"resource":{"primary":{"URL":"https:\/\/rmdopen.bmj.com\/lookup\/doi\/10.1136\/rmdopen-2020-001332"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9]]},"references-count":25,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2020,9,2]]},"published-print":{"date-parts":[[2020,9]]}},"alternative-id":["10.1136\/rmdopen-2020-001332"],"URL":"https:\/\/doi.org\/10.1136\/rmdopen-2020-001332","relation":{},"ISSN":["2056-5933"],"issn-type":[{"value":"2056-5933","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9]]}}}